- Home
- GDEN vs AVXL Comparison
GDEN vs AVXL Comparison
Compare GDEN & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- AVXL
- Stock Information
- Founded
- GDEN 1998
- AVXL 2004
- Country
- GDEN United States
- AVXL United States
- Employees
- GDEN N/A
- AVXL N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDEN Consumer Discretionary
- AVXL Health Care
- Exchange
- GDEN Nasdaq
- AVXL Nasdaq
- Market Cap
- GDEN 725.6M
- AVXL 710.3M
- IPO Year
- GDEN 1999
- AVXL N/A
- Fundamental
- Price
- GDEN $28.98
- AVXL $9.09
- Analyst Decision
- GDEN Buy
- AVXL Strong Buy
- Analyst Count
- GDEN 6
- AVXL 2
- Target Price
- GDEN $37.00
- AVXL $44.00
- AVG Volume (30 Days)
- GDEN 198.2K
- AVXL 768.8K
- Earning Date
- GDEN 08-07-2025
- AVXL 08-05-2025
- Dividend Yield
- GDEN 3.50%
- AVXL N/A
- EPS Growth
- GDEN N/A
- AVXL N/A
- EPS
- GDEN 0.39
- AVXL N/A
- Revenue
- GDEN $653,614,000.00
- AVXL N/A
- Revenue This Year
- GDEN $1.48
- AVXL N/A
- Revenue Next Year
- GDEN $2.88
- AVXL N/A
- P/E Ratio
- GDEN $74.60
- AVXL N/A
- Revenue Growth
- GDEN N/A
- AVXL N/A
- 52 Week Low
- GDEN $22.66
- AVXL $3.76
- 52 Week High
- GDEN $35.49
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- GDEN 59.86
- AVXL 64.24
- Support Level
- GDEN $26.81
- AVXL $7.97
- Resistance Level
- GDEN $28.15
- AVXL $9.35
- Average True Range (ATR)
- GDEN 0.80
- AVXL 0.38
- MACD
- GDEN 0.09
- AVXL 0.18
- Stochastic Oscillator
- GDEN 88.97
- AVXL 86.10
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.